To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

Inclusion Criteria: * Male or female participants between the ages of 18 and 80 years. * Participant has amyloid deposits confirmed by biopsy (Biopsy must have been performed within 5 years prior to enrollment). * Participant must have a TTR mutation that is associated with ATTR-PN (TTR mutation test must have been performed within 5 years prior to enrollment). * Participant has peripheral neuropathy at screening. * Participant has a Karnofsky Performance Status Score ≥50. * Stages of disease according to symptom severity-stage 1. Exclusion Criteria: * Participant has other causes of amyloidosis, such as light chain amyloidosis, AA amyloidosis. * Participant has used tafamidis within 2 months prior to enrollment. * Participant has used diflunisal, patisiran, inotersen, or other agents for familial amyloidosis within 30 days prior to enrollment or plan to use them during the study period. * Participant has used non-protocol NSAIDs more than 4 times within 30 days prior to enrollment or plan to use them more than 4 times per month during the study period. * Participant has used doxycycline,tauroursodeoxycholate within 14 days prior to enrollment or plan to use them during the study period. * Participant has sensory motor neuropathy caused by other causes, such as chronic inflammatory demyelinating polyradiculopathy, chronic idiopathic axonal neuropathy, diabetic neuropathy, chronic alcoholic neuropathy, paraneoplastic neuropathy,Guillain-Barre syndrome, vitamin B12 deficiency. * Participant has received liver or any other organ except cornea transplantation.